Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
about
Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic TrendThe risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanerceptAdalimumab for treating childhood plaque psoriasis: a clinical trial evaluation.Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.Juvenile idiopathic arthritis in multiplex families: longitudinal follow-up.Safety and effectiveness of etanercept for treatment of juvenile idiopathic arthritis: Results from a postmarketing surveillance.Risks of serious infections in children treated with biologic response-modifying drugs: Bacterial infection risk in children with juvenile idiopathic arthritis.Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate.
P2860
Q26741357-C464D4E3-0C23-49A8-8621-C1D7E916E883Q37274470-5A1F3D0B-54D3-40C9-82EC-897796219FD6Q37518319-A90C3821-8523-45CC-8DFD-FDD1E5EEBAF8Q38614496-7E27D6D5-CBAA-49B0-A99D-0A97A699604BQ38711172-29EFBB34-2EF9-4DA6-AF21-769578D4BD08Q38781266-1C484BC4-6B2A-47DF-A743-BEC0A2F5D0EAQ38817268-C5EC318A-7794-4479-8721-3E804FE76861Q40151899-08F9A31D-E9D4-4283-A315-0C2D704D4594Q40242247-6FA8C9A5-DD46-4D98-A6DD-523ACB1213BDQ47198925-683FA25C-7A0E-49B9-94D0-0A82CD585319Q47245015-00B6F539-840D-439D-966B-7A259627B42CQ52766696-96CEDE3B-C84E-4047-9C6E-896AB4A5A70B
P2860
Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Long-term safety of etanercept ...... le idiopathic arthritis (JIA).
@en
type
label
Long-term safety of etanercept ...... le idiopathic arthritis (JIA).
@en
prefLabel
Long-term safety of etanercept ...... le idiopathic arthritis (JIA).
@en
P2093
P2860
P1476
Long-term safety of etanercept ...... ile idiopathic arthritis (JIA)
@en
P2093
Angela Zink
Gerd Horneff
Hans-Iko Huppertz
Kirsten Minden
Martina Niewerth
P2860
P304
P356
10.1136/ANNRHEUMDIS-ANNRHEUMDIS-2014-206747
P407
P577
2015-04-29T00:00:00Z